中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2014年
35期
39-41
,共3页
奈达铂腹腔热灌注化疗%LV5-Fu2方案%胃肠道癌腹膜转移%癌性腹水
奈達鉑腹腔熱灌註化療%LV5-Fu2方案%胃腸道癌腹膜轉移%癌性腹水
내체박복강열관주화료%LV5-Fu2방안%위장도암복막전이%암성복수
Nedaplatin intraperitoneal hyperthermic perfusion chemotherapy%LV5-Fu2 scheme%Gastrointestinal peritoneal metastatic carcinoma%Malignant ascites
目的：研究晚期胃肠道癌合并癌性腹水病治疗中应用奈达铂（奥先达）腹腔热灌注化疗+LV5-Fu2方案的临床效果及安全性。方法：选取2012年6月-2014年6月在本院接受治疗的32例晚期胃肠道癌合并癌性腹水患者为研究对象，按随机数表法分为对照组与观察组，每组各16例。观察组行奈达铂（奥先达）腹腔热灌注化疗+LV5-Fu2方案治疗，对照组行常规LV5-Fu2方案治疗，观察两组患者的肿瘤病情缓解情况，腹腔积水的消退情况以及不良反应发生情况，比较两组的疗效及不良反应的差异。结果：观察组腹腔积水治疗总有效率87.5%显著高于对照组的50%，差异有统计学意义（P<0.05）；观察组的肿瘤缓解率56.25%显著高于对照组的37.5%，两组差异有统计学意义（P<0.05）；观察组的不良反应发生率为37.5%，对照组为31.25%，差异无统计学意义（P>0.05）。结论：晚期胃肠道癌合并癌性腹水患者应用奈达铂（奥先达）腹腔热灌注化疗+LV5-Fu2方案疗效显著，不良反应发生率与LV5-Fu2方案相当，有临床推广价值。
目的：研究晚期胃腸道癌閤併癌性腹水病治療中應用奈達鉑（奧先達）腹腔熱灌註化療+LV5-Fu2方案的臨床效果及安全性。方法：選取2012年6月-2014年6月在本院接受治療的32例晚期胃腸道癌閤併癌性腹水患者為研究對象，按隨機數錶法分為對照組與觀察組，每組各16例。觀察組行奈達鉑（奧先達）腹腔熱灌註化療+LV5-Fu2方案治療，對照組行常規LV5-Fu2方案治療，觀察兩組患者的腫瘤病情緩解情況，腹腔積水的消退情況以及不良反應髮生情況，比較兩組的療效及不良反應的差異。結果：觀察組腹腔積水治療總有效率87.5%顯著高于對照組的50%，差異有統計學意義（P<0.05）；觀察組的腫瘤緩解率56.25%顯著高于對照組的37.5%，兩組差異有統計學意義（P<0.05）；觀察組的不良反應髮生率為37.5%，對照組為31.25%，差異無統計學意義（P>0.05）。結論：晚期胃腸道癌閤併癌性腹水患者應用奈達鉑（奧先達）腹腔熱灌註化療+LV5-Fu2方案療效顯著，不良反應髮生率與LV5-Fu2方案相噹，有臨床推廣價值。
목적：연구만기위장도암합병암성복수병치료중응용내체박（오선체）복강열관주화료+LV5-Fu2방안적림상효과급안전성。방법：선취2012년6월-2014년6월재본원접수치료적32례만기위장도암합병암성복수환자위연구대상，안수궤수표법분위대조조여관찰조，매조각16례。관찰조행내체박（오선체）복강열관주화료+LV5-Fu2방안치료，대조조행상규LV5-Fu2방안치료，관찰량조환자적종류병정완해정황，복강적수적소퇴정황이급불량반응발생정황，비교량조적료효급불량반응적차이。결과：관찰조복강적수치료총유효솔87.5%현저고우대조조적50%，차이유통계학의의（P<0.05）；관찰조적종류완해솔56.25%현저고우대조조적37.5%，량조차이유통계학의의（P<0.05）；관찰조적불량반응발생솔위37.5%，대조조위31.25%，차이무통계학의의（P>0.05）。결론：만기위장도암합병암성복수환자응용내체박（오선체）복강열관주화료+LV5-Fu2방안료효현저，불량반응발생솔여LV5-Fu2방안상당，유림상추엄개치。
Objective:To investigate the clinical effect and safety of nedaplatin intraperitoneal hyperthermic perfusion chemotherapy plus LV5-Fu2 in treatment of advanced gastrointestinal carcinoma complicated with ascites. Method:32 patients of advanced gastrointestinal carcinoma complicated with ascites treated in our hospital from June 2012 to June 2014 were selected as the research objects and divided into control group and observation group by a random number table,16 cases in each group.The observation group were treated with nedaplatin(Austrian Xianda)intraperitoneal hyperthermic perfusion chemotherapy plus LV5-Fu2,and the control group were routinely treated with LV5-Fu2.The curative effect and the difference of adverse reaction between the two groups were compared by observing tumor remission status ,the occurence of abdominal seeper subsiding and adverse reaction.Result:The total effective rate of observation group for abdominal dropsy was 87.5%,significantly higher than 50%of the control group,the difference was statistically significant(P<0.05);the tumor remission rate of the observation group was 56.25%,significantly higher than 37.5%of the control group,and the difference between two groups was statistically significant(P<0.05).The incidence of adverse action of the observation group was 37.5%,higher than 31.25%of the control group,but the difference was not statistically significant(P>0.05).Conclusion:The application of nedaplatin(Austrian Xianda)intraperitoneal hyperthermic perfusion chemotherapy plus LV5-Fu2 scheme in patients of advanced gastrointestinal cancer complicated with ascites has marked effect and quite effect with LV5-Fu2 scheme in the rate of adverse reactions,so it has clinical value.
